Crescentic glomerulonephritis associated with vascular endothelial growth factor (VEGF) inhibitor and bisphosphonate administration

Nephrology Dialysis Transplantation

Volumn 26, Issue 5, 2011, Pages 1742-1745

  Stylianou, Kostas ^a   Lioudaki, Eirini ^a   Papadimitraki, Elisavet ^a   Kokologiannakis, George ^a   Kroustalakis, Nikos ^a   Liotsi, Christina ^a   Giannakakis, Konstantinos ^b   Georgoulias, Vasilios ^a   Daphnis, Eugenios ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

bevacizumab; crescentic glomerulonephritis; zolendronate

Indexed keywords

AMLODIPINE; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CREATININE; DOXORUBICIN; ETOPOSIDE; FIBRINOGEN; FUROSEMIDE; HAPTOGLOBIN; IMMUNOGLOBULIN M; IRINOTECAN; LACTATE DEHYDROGENASE; PACLITAXEL; PEMETREXED; RAMIPRIL; ZOLEDRONIC ACID;

ACUTE KIDNEY FAILURE; AGED; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; BRAIN RADIATION; CASE REPORT; CREATININE BLOOD LEVEL; CRESENTIC GLOMERULONEPHRITIS; DYSPNEA; ECHOGRAPHY; FEVER; GLOMERULONEPHRITIS; HEMATURIA; HEMODIALYSIS; HIP; HUMAN; HYPERTENSION; IMMUNOFLUORESCENCE TEST; KIDNEY BIOPSY; LIVER METASTASIS; LUNG EDEMA; LUNG SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NORMOCHROMIC NORMOCYTIC ANEMIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGURIA; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROTEINURIA; SIDE EFFECT; THORAX PAIN; THROMBOTIC THROMBOCYTOPENIC PURPURA; URINALYSIS;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DRUG THERAPY, COMBINATION; GLOMERULONEPHRITIS; HUMANS; IMIDAZOLES; LUNG NEOPLASMS; MALE; RENAL DIALYSIS; SMALL CELL LUNG CARCINOMA; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79955624389     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr093     Document Type: Article

References (15)

1. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004; 25: 581-611 (Pubitemid 39099316)
2. Miles D. Management of toxicity in patients receiving therapy with bevacizumab. Eur J Cancer Suppl 2008; 6: 29-39
3. Zhu X, Wu S, Dahut WL et al. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 2007; 49: 186-193 (Pubitemid 46178407)
4. Ranpura V, Pulipati B, Chu D et al. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens 2010; 23: 460-468
5. Wu S, Kim C, Baer L et al. Bevacizumab increases risk for severe pro-teinuria in cancer patients. JAm Soc Nephrol 2010; 21: 1381-1389
6. Markowitz GS, Appel GB, Fine PL et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 2001; 12: 1164-1172 (Pubitemid 32472629)
7. Miller KD, Chap LI, Holmes FA et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23: 792-799 (Pubitemid 46224178)
8. Eremina V, Jefferson JA, Kowalewska J et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008; 358: 1129-1136 (Pubitemid 351398487)
9. Stokes MB, Erazo MC, DAgati VD. Glomerular disease related to anti-VEGF therapy. Kidney Int 2008; 74: 1487-1491
10. Johnson DH, Fehrenbacher L, Novotny WF et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22: 2184-2191 (Pubitemid 41095154)
11. George BA, Zhou XJ, Toto R. Nephrotic syndrome after bevacizumab: case report and literature review. Am J Kidney Dis 2007; 49: e23-e29 (Pubitemid 46164815)
12. Izzedine H, Massard C, Spano JP et al. VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management. Eur J Cancer 2010; 46: 439-448
13. Eremina V, Sood M, Haigh J et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003; 111: 707-716 (Pubitemid 36278589)
14. Ziyadeh FN, Wolf G Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Curr Diabetes Rev 2008; 4: 39-45 (Pubitemid 351210971)
15. Bodmer M, Amico P, Mihatsch MJ et al. Focal segmental glomerulo-sclerosis associated with long-term treatment with zoledronate in a myeloma patient. Nephrol Dial Transplant 2007; 22: 2366-2370 (Pubitemid 47244720)